טוען...
Sequential Therapy With JX-594, A Targeted Oncolytic Poxvirus, Followed by Sorafenib in Hepatocellular Carcinoma: Preclinical and Clinical Demonstration of Combination Efficacy
JX-594 is a targeted and granulocyte-macrophage colony stimulating factor (GM-CSF) expressing oncolytic poxvirus designed to selectively replicate in and destroy cancer cells through viral oncolysis and tumor-specific immunity. In a phase 1 trial, JX-594 injection into hepatocellular carcinoma (HCC)...
שמור ב:
Main Authors: | , , , , , , , , , , , , , , , , |
---|---|
פורמט: | Artigo |
שפה: | Inglês |
יצא לאור: |
Nature Publishing Group
2011
|
נושאים: | |
גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3129795/ https://ncbi.nlm.nih.gov/pubmed/21427706 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/mt.2011.39 |
תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|